Pain Management Following TRAM Flap for Breast Reconstruction

Completed · Not applicable

Conditions studied: Breast Cancer

In brief

The objective of this pilot study is to examine the efficacy of the ON\~Q Pain Relief System plus Intravenous Patient Controlled Analgesia (IVPCA) with Morphine vs IV PCA alone in patients undergoing free transverse rectus abdominis musculocutaneous (TRAM) flap surgery. The primary outcome measure will be postoperative opioid analgesia requirements. Other outcomes will also be assessed, including pain scores, quality of recovery, and resource utilization.

Key facts

Study ID

NCT00500565

Run by

M.D. Anderson Cancer Center

People needed

61

Starts

2003-12-01

Expected to finish

2008-06-01

Last updated by the study team

2013-10-11

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with or undergoing unilateral elective free TRAM flap for breast reconstruction, immediate or delayed, with or without a surgical revision of the contralateral breast for asymmetry.
• American Society of Anesthesiology Physical Status I - III patients.
• Patients has given voluntary written informed consent before performance of any study-related procedure.

You may not qualify if…

• Patients undergoing bilateral TRAM flap reconstruction.
• Patients with a prior allergic reaction to Marcaine (bupivacaine) or other amide local anesthetics.
• Patients with a prior allergic reaction to Morphine and Hydromorphone.
• Patients undergoing any other unrelated surgical procedure to the breast reconstruction.
• Patient refusal to participate.
• Patient required major abdominal surgery within four weeks prior to enrollment.
• Patients being treated for chronic pain or using daily intake of opioid analgesics.
• Patients with a history of abuse of recreational drugs or alcohol.
• Patients with any laboratory values or underlying disease, which in the investigator's opinion would preclude them from participation in the trial, specifically: (A) significant liver dysfunction (eg. bilirubin, AST and/or ALT >1.5 times the upper limit of normal value (B) cardiac conduction defects noted by history or on the pre-op screening EKG.
• Pregnant or breast feeding.

Where it is running

• U.T.M.D. Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.